


**Hematologies, Inc.**

3161 Elliott Ave Suite 200  
Seattle, WA 98121  
(206) 223-2700 or (800) 860-0934  
Fax (206) 223-5550  
www.hematologies.com

HLID#: PATIENT NAME: Patient Name  
PATIENT ID#: DOB : SEX:  
NPI: ORDERING PHYSICIAN:  
SPECIMEN TYPE: Peripheral Blood  
COLLECTION DATE: RECEIPT DATE:  
REPORT DATE: ICD-9: 205.00 UNITS:  
CLINIC ID#: ACCOUNT:  
CPT: 83913/81206/81207/83900/83901/83902/83912

**Patient Name****Specimen Type:** Peripheral Blood**Clinical History/Indications:** A xx year old female with a clinical history of acute myelogenous leukemia (AML).**WT-1 RT-PCR Results: LOW POSITIVE**

| Date      | HLID# | Specimen | WT1 NCN | % Reduction | Log Reduction |
|-----------|-------|----------|---------|-------------|---------------|
| 10/1/2012 | xxx   | BMA      | 0.007   | Baseline    | Baseline      |
| 5/1/2013  | xxx   | BMA      | 0.001   | 85.2        | 0.8           |

**NCN (normalized copy numbers): 0.001**

Quantitative assay units: WT1/ABL transcript levels are reported as a ratio of target gene transcript / ABL reference gene transcript.

**Analysis/Conclusions:**

The specimen tested low positive for Wilms Tumor gene (WT1) transcript which has been described in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)<sup>1,2</sup>.

- **The quantitative WT-1 NCN value of 0.001 is reduced by 85.2% (log reduction 0.8) in comparison to the diagnostic patient specimen.**
- Clinical and histological correlation is required for definitive diagnosis.

Control gene amplification indicated adequate RNA quality in this specimen.

This test amplifies the WT1 cDNA sequence, detecting five different splice variants of the WT1 gene with a sensitivity level of > 1 in 10e4 transcripts (0.01 %).

**Method:**

RNA is isolated from the sample provided and converted into cDNA using reverse transcriptase and amplified by real-time polymerase chain reaction (RQ-PCR) for the WT1 gene.

Although molecular testing is highly accurate, rarely false-positive and false-negative diagnostic errors may occur.

DW/MRL/BZ

**References:**

1. Lapillonne, H. *et al.* High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* **24**, 1507–1515 (2006).
2. Tamaki, H. *et al.* The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. *Leukemia* **13**, 393–399 (1999).

Electronically signed by: Barbara K. Zehentner, Ph.D., HCLD (ABB), Director of Molecular Analysis and Denise A. Wells, MD, Medical Director

This test was developed and its performance characteristics determined by HematoLogics, Inc. It has not been cleared or approved by the US Food and Drug Administration